JAK2 and myeloproliferative neoplasm: Furthermore, in some leukemias and myeloproliferative neoplasms, constitutive JAK2 activation (V617F mutation) drives malignant transformation [27] and this prompted a significant effort in targeting JAK2 inhibition as a potential therapeutic strategy.